What is new in iPrEx?
AVDAC Recommends FTC/TDF
For the prevention of HIV infection in adults as PrEP
• • • • • •
iPrEx and the Supplemental New Drug Application of Truvada for PrEP
• • • • • •
AIDS Advocates Support FDA Approval of PrEP
Urgent Need of New HIV Prevention Tools to End AIDS
• • • • • •
UC will test HIV prevention pills
• • • • • •
FDA finalizes Audits at Global iPrEx in South America
No critical issues in the implementation of the study.
• • • • • •
FDA performs visit inspection to the Ecuador site
To check the conduction of the Global iPrEx
• • • • • •
Truvada Priority Review
U.S.Food and Drug Administration (FDA)
• • • • • •
Launch of first pre-HIV exposure prevention trial for gay men in Europe
IPERGAY is a French ANRS initiative
• • • • • •
FDA asked to approve NEW HIV PREVENTION METHOD
Gilead submitted supplemental New Drug Application (sNDA)
• • • • • •
Bob Grant People who Mattered in 2011
• • • • • •
VOICE DSMB Recommends Stopping Tenofovir Gel Arm
NIAID has made a public announcement on November 25, 2011
• • • • • •
iPrEx OLE: 279 additional participants
CDC Project T will Join the study
• • • • • •
Unblinding iPrEx
iPrEx study sites have been unblinding participants since June of 2011
• • • • • •
PrEP Demonstration Projects about to be Launched
San Francisco will be the first city in the United States
• • • • • •
6th IAS Conference
New data confirm eficacy and safety of PrEP
• • • • • •
iPrEx OLE begins at 11 sites in six countries
iPrEx OLE to Build on News that PrEP Slows HIV Infections
• • • • • •
News on Partners PrEP and CDC Botswana
Studies detailing the safety and effectiveness of PrEP
• • • • • •
The FACTS 001 tenofovir gel study
• • • • • •
Intermittent PrEP
• • • • • •
30 years into the epidemic
• • • • • •
News on HPTN 052
Another HIV Prevention Trial Shows Success
• • • • • •
News on FEM-PrEP
FEM-PrEP trial is stopped by the IDMC
• • • • • •
CROI 2011
iPrEx presented new data in the conference in Boston
iPrEx CROI release
• • • • • •
US Centers for Disease Control and Prevention (CDC)
iPrEx, or Pre-Exposure Prophylaxis Initiative is a clinical trial aimed at determining whether two antiretroviral (ARV) medications used to treat HIV/AIDS help prevent HIV acquisition in HIV-uninfected people at high risk of infection.